Titan Biotech Ltd

Titan Biotech Limited announced that its board of directors approved the allotment of 1,03,29,625 fully paid-up bonus equity shares of Rs 2 each in the ratio of 1:4 to eligible shareholders as on October 23, 2026, following shareholder approval at the 34th Annual General Meeting on September 29, 2026. The company’s paid-up equity share capital will increase from 4,13,18,500 shares with a total value of Rs 8,26,37,000 to 5,16,48,125 shares with a total value of Rs 10,32,96,250.

Titan Biotech Limited informed the BSE Ltd. that it has received an in-principal approval to issue and allot 10,329,625 bonus equity shares of Rs 2 each in a 1:4 ratio, following shareholder approval at its 34th Annual General Meeting on September 29, 2026; the company fixed October 23, 2026, as the record date and October 26, 2026, as the deemed date of allotment for the bonus shares, with trading expected to commence on Tuesday, October 27, 2026.

Titan Biotech Limited submitted a confirmation certificate to the BSE Limited on October 7, 2026, regarding Regulation 74(5) of the Securities and Exchange Board of India (Depositories and participants) Regulations 2018, as confirmed by its Registrar & Share Transfer Agent, Beetal Financial & Computer Services (P) Ltd, on October 5, 2026, pertaining to securities dematerialized during the quarter ended September 2026.

Titan Biotech Limited informed the BSE Ltd. that at its 34th Annual General Meeting on September 29, 2026, shareholders approved an increase in the company’s authorized share capital from Rs 10,00,00,000 divided into 5,00,00,000 equity shares of Rs 2 each to Rs 10,40,00,000 divided into 5,20,00,000 equity shares of Rs 2 each, resulting in the creation of 20,00,000 new equity shares and a consequent alteration of the “Capital Clause” of the company’s Memorandum of Association.

Titan Biotech Limited informed the BSE Limited that the trading window for dealing in the company's securities will be closed from October 1, 2026, until 48 hours after the declaration of unaudited financial results (standalone & consolidated) for the quarter and half year ending September 30, 2026, for designated persons, their immediate relatives, and connected persons.

Titan Biotech Limited will hold its Thirty-Fourth Annual General Meeting on September 29, 2026, at 3:00 p.m. (IST) via video conferencing, with the Register of Members closed from September 23, 2026, to September 29, 2026, and a record date set for September 22, 2026, to determine eligibility for the final dividend for the financial year ended March 31, 2026. E-voting will be available from September 26, 2026, at 10:00 a.m. (IST) to September 28, 2026, at 5:00 p.m. (IST), with September 22, 2026, as the cut-off date.

Titan Biotech Limited announced several key decisions following a board meeting, informing the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE). The company will issue bonus shares in a ratio of 1:4, requiring Rs 2,06,59,250 and with an estimated credit/dispatch date of November 3, 2026. Simultaneously, the authorized share capital will increase from Rs 10,00,00,000 to Rs 10,40,00,000, expanding the company’s capacity to issue shares. Additionally, the board re-appointed Mr. Rohit Jain as an Independent Director for a five-year term, from September 30, 2026, to September 29, 2031. Mr. Jain, a Partner at Singhania & Co. LLP, brings extensive legal and corporate experience to the role.

Titan Biotech Limited has fixed September 22, 2026, as the record date for determining entitlement of members to a final dividend of Rs 0.50 per equity share of Rs 2 each for the financial year ended March 31, 2026, following a recommendation by the board of directors on May 30, 2026.

Titan Biotech Limited will seek shareholder approval for a bonus share issue at a board meeting scheduled for Thursday, September 3, 2026, according to a regulatory filing with the BSE Ltd. on August 31, 2026. The company has also closed its trading window for designated persons from August 31, 2026, and it will remain closed for 48 hours after the outcome of the board meeting is declared.

Titan Biotech Limited will close its trading window for all designated persons, their immediate relatives, and connected persons from August 31, 2026, until 48 hours after the conclusion of a board meeting scheduled for September 3, 2026, to consider a proposal for the issue of bonus shares, according to a filing with the BSE Limited.